MedPath

Virtual Reality and Concept of Control in the Treatment of Acrophobia

Not Applicable
Conditions
Phobic Disorders
Registration Number
NCT02020824
Lead Sponsor
Qualissima
Brief Summary

Virtual reality is currently used as a therapeutic strategy in common phobia as agoraphobia or acrophobia, since it permits to have a better control (on occurrence of events or on the environment) during the therapy than in "in vivo" therapy. Our hypothesis here is that we can improves the therapeutic effects of the virtual exposure by giving control to acrophobic patients during their exposure.

Detailed Description

The study is based on the exposure of acrophobic patients to virtual environments. During the study, several groups of patients will be distributed according to different conditions: exposure to anxiogenous virtual environments and exposure with the ability to control and secure the anxiogenous virtual environments.

The interest of this project is to improve therapy by exposure to virtual reality. Our project offers a systematic therapeutic approach (using virtual reality and the concept of control) where current therapy are too often approximate. We aim to demonstrate the effectiveness of the control of virtual environments on symptomatic and psychophysiological levels, to evaluate the adoption of these methods in the couple patients-caregivers and also to understand the brain mechanisms (including those prefrontal) involved in this therapy.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Behavioural Avoidance Test (BAT)1 year (4 times)

Objective measure of behavior scored on 10 points in response to a virtual environment representing a situation feared by acrophobic patients. This virtual environment is a flat landscape with a platform overlooking a canyon of 800 meters.

Secondary Outcome Measures
NameTimeMethod
Ergonomy10 weeks (8 times)

During the 8 sessions of exposure to virtual reality: Questionnaire on the applicability / realism / ergonomy (PQ: Questionnaire on the state of Presence).

Adverse events1 year

Assessment and description of all the occurrence of adverse events during the study.

Quality of life1 year (4 times)

Quality of Life (SF-12: Medical Outcome Study Short Form)

Psychophysiological10 weeks (8 times)

During the 8 sessions of exposure to virtual reality: Psychophysiological objective measurements during exposure to virtual reality (electrodermal activity, electrocardiography, breathing rate)

Cognitive measurements10 weeks (8 times)

During the 8 sessions of exposure to virtual reality: Progression recorded and time to progression from one environment to another during sessions (number of environments completed, time of execution, others ..)

Brain activity (functional MRI)12 weeks (2 times)

Anatomical and functional : brain activity in several cortical and subcortical areas with fMRI (BOLD signal intensity)

Synaptic activity (PET-scan)12 weeks (2 times)

Metabolic and functional : synaptic activity with PET scanner

Trial Locations

Locations (1)

Service hospitalo-universitaire de psychologie médicale de psychiatrie d'adultes du Pr Lançon - CHU Marseille

🇫🇷

Marseille, France

Service hospitalo-universitaire de psychologie médicale de psychiatrie d'adultes du Pr Lançon - CHU Marseille
🇫🇷Marseille, France
Eric MALBOS, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.